Jobs / United States / Glaxosmithkline LLC
Clinical Biomarker Lead- Oncology Translational Medicine
Glaxosmithkline LLC · 🇺🇸 3 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles1 certified filing for “Sr Manager - Oncology Commercial Analytics, Multiple Myeloma” (Data Scientists) in PA: $135k–$135k, median $135k. Most were filed at wage level III (100%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
’For candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to [Cambridge, UK] [Ware]. The location of this role will therefore subsequently change to [Cambridge, UK] [Ware] in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029 Business Introduction At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success. We’re uniting science, technology, and talent to get ahead of disease together. Find out more: Our approach to R&D Position Summary Are you interested in the development and effective implementation of biomarker strategy to support clinical development across GSK portfolio? Are you searching for a position where you will be working as a key contributor leading development of novel biomarkers for clinical trials and/or as a biomarker lead on clinical matrix team (CMT) and leading development and integration of biomarker strategy into clinical development plans? If so, the Assoc. Director Biomarkers in OTM could be an ideal opportunity to explore. Key Responsibilities This role will provide YOU the opportunity to lead key activities to progress YOUR career. These responsibilities include some of the following: • Work with key external industry and/or academic partners to evaluate, validate and establish key biomarker capabilities and/or generate key biomarker data to support biomarker strategies for clinical trial implementation at GSK. You will be responsible for designing, implementing and managing collaborative projects that aid in developing biomarker capabilities that are of strategic importance to OTM and in alignment with GSK clinical trials. • Identify, develop and implement cutting edge advances in science and technology into biomarker strategies to guide indication selection, patient enrichment, and combination strategies. • Provide input to clinical biomarker teams on novel technologies that will enable clinical development of GSK candidate drugs. • Manage effective working relationships with clinical biomarker leads, medical affairs, oncology tumor teams, portfolio management, competitive intelligence, clinical development and OTM management. • Coordinate and manage biomarker projects with cross-functional internal stakeholders and external partners • Contribute to and ensure the quality of OTM biomarker reports, summaries, data reviews and interpretations as applicable. Present key data/findings/accomplishments at internal as well as external scientific forums, lead the preparation and publication of scientific manuscripts as needed. Why You? Basic Qualification We are seeking professionals with the following required skills and qualifications to help us achieve our goals: • Ph.D. or equivalent with 3+ years or M.Sc with 7+ years of drug development experience in pharmaceutical industry preferably in oncology biomarker development. • Experience with biomarker assays, technologies, platforms and providers. • Experience of implementation of a range of biomarker platforms including flow cytometry, molecular diagnostics (NGS, FISH, PCR), and/or IHC/IF for Oncology clinical trials. • Experience designing and executing translational biomarker